Even your weight loss drugs aren't safe from tariffs
Catia Tănase
In This Story NVO -2.08% LLY -0.69% PFE +0.60% Novo Nordisk ( NVO -2.08% ) , the maker of the popular diabetes and weight-loss drugs Ozempic and Wegovy, expects at least some short-term impacts from President Donald Trump’s proposed tariffs. Suggested Reading Trump's trade war and DOGE's work caused a 245% surge in U.S. layoff announcements Trade wars have no winners, S&P economists say, trimming GDP forecasts Delta announces aircraft of the not-too-distant future Ozempic competitor in the
din zilele anterioare